<script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app16.us.archive.org';v.server_ms=242;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include --><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<script type="text/javascript" src="/static/js/timestamp.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/graph-calc.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/auto-complete.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/toolbar.js?v=1531166943.0" charset="utf-8"></script>

<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
.wb-autocomplete-suggestions {
    text-align: left; cursor: default; border: 1px solid #ccc; border-top: 0; background: #fff; box-shadow: -1px 1px 3px rgba(0,0,0,.1);
    position: absolute; display: none; z-index: 2147483647; max-height: 254px; overflow: hidden; overflow-y: auto; box-sizing: border-box;
}
.wb-autocomplete-suggestion { position: relative; padding: 0 .6em; line-height: 23px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis; font-size: 1.02em; color: #333; }
.wb-autocomplete-suggestion b { font-weight: bold; }
.wb-autocomplete-suggestion.selected { background: #f0f0f0; }
</style>
<div id="wm-ipp" lang="en" style="display:none;direction:ltr;">
<div style="position:fixed;left:0;top:0;right:0;">
<div id="wm-ipp-inside">
  <div style="position:relative;">
    <div id="wm-logo" style="float:left;width:130px;padding-top:10px;">
      <a href="/web/" title="Wayback Machine home page"><img src="/static/images/toolbar/wayback-toolbar-logo.png" alt="Wayback Machine" width="110" height="39" border="0" /></a>
    </div>
    <div class="r" style="float:right;">
      <div id="wm-btns" style="text-align:right;height:25px;">
                  <div id="wm-save-snapshot-success">success</div>
          <div id="wm-save-snapshot-fail">fail</div>
          <a href="#"
             onclick="__wm.saveSnapshot('https://www.guideline.gov/summaries/downloadcontent/ngc-10541?contentType=xml', '20180713001949')"
             title="Share via My Web Archive"
             id="wm-save-snapshot-open"
          >
            <span class="iconochive-web"></span>
          </a>
          <a href="https://archive.org/account/login.php"
             title="Sign In"
             id="wm-sign-in"
          >
            <span class="iconochive-person"></span>
          </a>
          <span id="wm-save-snapshot-in-progress" class="iconochive-web"></span>
        	<a href="http://faq.web.archive.org/" title="Get some help using the Wayback Machine" style="top:-6px;"><span class="iconochive-question" style="color:rgb(87,186,244);font-size:160%;"></span></a>
	<a id="wm-tb-close" href="#close" onclick="__wm.h(event);return false;" style="top:-2px;" title="Close the toolbar"><span class="iconochive-remove-circle" style="color:#888888;font-size:240%;"></span></a>
      </div>
      <div id="wm-share" style="text-align:right;">
	<a href="#" onclick="window.open('https://www.facebook.com/sharer/sharer.php?u=https://web.archive.org/web/20180713001949/https://www.guideline.gov/summaries/downloadcontent/ngc-10541?contentType=xml', '', 'height=400,width=600'); return false;" title="Share on Facebook" style="margin-right:5px;" target="_blank"><span class="iconochive-facebook" style="color:#3b5998;font-size:160%;"></span></a>
	<a href="#" onclick="window.open('https://twitter.com/intent/tweet?text=https://web.archive.org/web/20180713001949/https://www.guideline.gov/summaries/downloadcontent/ngc-10541?contentType=xml&amp;via=internetarchive', '', 'height=400,width=600'); return false;" title="Share on Twitter" style="margin-right:5px;" target="_blank"><span class="iconochive-twitter" style="color:#1dcaff;font-size:160%;"></span></a>
      </div>
    </div>
    <table class="c" style="">
      <tbody>
	<tr>
	  <td class="u" colspan="2">
	    <form target="_top" method="get" action="/web/submit" name="wmtb" id="wmtb"><input type="text" name="url" id="wmtbURL" value="https://www.guideline.gov/summaries/downloadcontent/ngc-10541?contentType=xml" onfocus="this.focus();this.select();" /><input type="hidden" name="type" value="replay" /><input type="hidden" name="date" value="20180713001949" /><input type="submit" value="Go" /></form>
	  </td>
	  <td class="n" rowspan="2" style="width:110px;">
	    <table>
	      <tbody>
		<!-- NEXT/PREV MONTH NAV AND MONTH INDICATOR -->
		<tr class="m">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20180610072745/https://www.guideline.gov/summaries/downloadcontent/ngc-10541?contentType=xml" title="10 Jun 2018"><strong>Jun</strong></a></td>
		  <td class="c" id="displayMonthEl" title="You are here: 00:19:49 Jul 13, 2018">JUL</td>
		  <td class="f" nowrap="nowrap">Aug</td>
		</tr>
		<!-- NEXT/PREV CAPTURE NAV AND DAY OF MONTH INDICATOR -->
		<tr class="d">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20180610072745/https://www.guideline.gov/summaries/downloadcontent/ngc-10541?contentType=xml" title="07:27:45 Jun 10, 2018"><img src="/static/images/toolbar/wm_tb_prv_on.png" alt="Previous capture" width="14" height="16" border="0" /></a></td>
		  <td class="c" id="displayDayEl" style="width:34px;font-size:24px;white-space:nowrap;" title="You are here: 00:19:49 Jul 13, 2018">13</td>
		  <td class="f" nowrap="nowrap"><img src="/static/images/toolbar/wm_tb_nxt_off.png" alt="Next capture" width="14" height="16" border="0" /></td>
		</tr>
		<!-- NEXT/PREV YEAR NAV AND YEAR INDICATOR -->
		<tr class="y">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20160930212522/https://www.guideline.gov/summaries/downloadcontent/ngc-10541?contentType=xml" title="30 Sep 2016"><strong>2016</strong></a></td>
		  <td class="c" id="displayYearEl" title="You are here: 00:19:49 Jul 13, 2018">2018</td>
		  <td class="f" nowrap="nowrap">2019</td>
		</tr>
	      </tbody>
	    </table>
	  </td>
	</tr>
	<tr>
	  <td class="s">
	    	    <div id="wm-nav-captures">
	      	      <a class="t" href="/web/20180713001949*/https://www.guideline.gov/summaries/downloadcontent/ngc-10541?contentType=xml" title="See a list of every capture for this URL">6 captures</a>
	      <div class="r" title="Timespan for captures of this URL">30 Sep 2016 - 13 Jul 2018</div>
	      </div>
	  </td>
	  <td class="k">
	    <a href="" id="wm-graph-anchor">
	      <div id="wm-ipp-sparkline" title="Explore captures for this URL" style="position: relative">
		<canvas id="wm-sparkline-canvas" width="575" height="27" border="0"></canvas>
	      </div>
	    </a>
	  </td>
	</tr>
      </tbody>
    </table>
    <div style="position:absolute;bottom:0;right:2px;text-align:right;">
      <a id="wm-expand" class="wm-btn wm-closed" href="#expand" onclick="__wm.ex(event);return false;"><span id="wm-expand-icon" class="iconochive-down-solid"></span> <span style="font-size:80%">About this capture</span></a>
    </div>
  </div>
    <div id="wm-capinfo" style="border-top:1px solid #777;display:none; overflow: hidden">
            <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center">COLLECTED BY</div>
    <div style="padding:3px;position:relative" id="wm-collected-by-content">
            <div style="display:inline-block;vertical-align:top;width:50%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/archiveteam);"></span>
		Organization: <a style="color:#33f;" href="https://archive.org/details/archiveteam" target="_new"><span class="wm-title">Archive Team</span></a>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  <img align=right src="http://archiveteam.org/images/e/e6/Archiveteam.jpg" width=200> Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed of volunteers and interested parties, and has expanded into a large amount of related projects for saving online and digital history.
<p>
History is littered with hundreds of conflicts over the future of a community, group, location or business that were "resolved" when one of the parties stepped ahead and destroyed what was there. With the original point of contention destroyed, the debates would fall to the wayside. Archive Team believes that by duplicated condemned data, the conversation and debate can continue, as well as the richness and insight gained by keeping the materials. Our projects have ranged in size from a single volunteer downloading the data to a small-but-critical site, to over 100 volunteers stepping forward to acquire terabytes of user-created data to save for future generations.
<p>
The main site for Archive Team is at <a href="http://www.archiveteam.org">archiveteam.org</a> and contains up to the date information on various projects, manifestos, plans and walkthroughs.
<p>
This collection contains the output of many Archive Team projects, both ongoing and completed. Thanks to the generous providing of disk space by the Internet Archive, multi-terabyte datasets can be made available, as well as in use by the <a href="http://archive.org/web/web.php">Wayback Machine</a>, providing a path back to lost websites and work. 
<p>
Our collection has grown to the point of having sub-collections for the type of data we acquire. If you are seeking to browse the contents of these collections, the Wayback Machine is the best first stop. Otherwise, you are free to dig into the stacks to see what you may find.
<p>
<b>The Archive Team Panic Downloads</b> are full pulldowns of currently extant websites, meant to serve as emergency backups for needed sites that are in danger of closing, or which will be missed dearly if suddenly lost due to hard drive crashes or server failures. 
<p>
	</div>
	      </div>
      <div style="display:inline-block;vertical-align:top;width:49%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/archivebot)"></span>
		<div>Collection: <a style="color:#33f;" href="https://archive.org/details/archivebot" target="_new"><span class="wm-title">ArchiveBot: The Archive Team Crowdsourced Crawler</span></a></div>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  ArchiveBot is an IRC bot designed to automate the archival of smaller websites (e.g. up to a few hundred thousand URLs). You give it a URL to start at, and it grabs all content under that URL, records it in a WARC, and then uploads that WARC to ArchiveTeam servers for eventual injection into the Internet Archive (or other archive sites).
<p>
To use ArchiveBot, drop by #archivebot on EFNet. To interact with ArchiveBot, you issue commands by typing it into the channel. Note you will need channel operator permissions in order to issue archiving jobs. The dashboard shows the sites being downloaded currently.
<p>
There is a dashboard running for the archivebot process at <a href="http://www.archivebot.com">http://www.archivebot.com</a>.
<p>
ArchiveBot's source code can be found at <a href="https://github.com/ArchiveTeam/ArchiveBot">https://github.com/ArchiveTeam/ArchiveBot</a>.
	</div>
	      </div>
    </div>
    <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center" title="Timestamps for the elements of this page">TIMESTAMPS</div>
    <div>
      <div id="wm-capresources" style="margin:0 5px 5px 5px;max-height:250px;overflow-y:scroll !important"></div>
      <div id="wm-capresources-loading" style="text-align:left;margin:0 20px 5px 5px;display:none"><img src="/static/images/loading.gif" alt="loading" /></div>
    </div>
  </div></div></div></div><script type="text/javascript">
__wm.bt(575,27,25,2,"web","https://www.guideline.gov/summaries/downloadcontent/ngc-10541?contentType=xml","2018-07-13",1996);
</script>
<!-- END WAYBACK TOOLBAR INSERT --><version>
  <xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource>
  <section secid="390" ordby="100" name="General">
    <field fieldid="161" ordby="105" id="391" name="Guideline Title" type="text">
      <fieldvalue value="<div class=&quot;content_title&quot;>Intraoperative tests (RD-100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer.</div>"/>
    </field>
    <field fieldid="97" ordby="110" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>National Institute for Health and Care Excellence (NICE). Intraoperative tests (RD-100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer. London (UK): National Institute for Health and Care Excellence (NICE); 2013 Aug. 40 p.&amp;nbsp;(Diagnostics guidance; no. 8).&amp;nbsp;</td></tr></table>"/>
    </field>
    <field fieldid="120" ordby="115" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p>
<p>This guideline meets NGC's 2013 (revised) inclusion criteria.</p></div>"/>
    </field>
  </section>
  <section secid="420" ordby="300" name="Recommendations">
    <field fieldid="151" ordby="310" id="421" name="Major Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Whole lymph node analysis using the RD-100i OSNA system is recommended as an option for detecting sentinel lymph node metastases during breast surgery in people with early invasive breast cancer who have a sentinel lymph node biopsy and in whom axillary lymph node dissection will be considered. Details of the development of a national registry are included in Section 7 in the original guideline document.</p>
<p>The Metasin test is not recommended for detecting sentinel lymph node metastases in people with early invasive breast cancer in routine clinical National Health Service (NHS) practice. The Metasin test shows promise and the development of robust evidence is recommended to demonstrate its utility in clinical practice.</p></div>"/>
    </field>
    <field fieldid="138" ordby="330" id="423" name="Clinical Algorithm(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None provided</p></div>"/>
    </field>
  </section>
  <section secid="396" ordby="400" name="Scope">
    <field fieldid="140" ordby="405" id="397" name="Disease/Condition(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Breast cancer (early invasive with axillary lymph node metastasis)</p></div>"/>
    </field>
    <field fieldid="103" ordby="410" id="398" name="Guideline Category" type="picklist-many">
      <fieldvalue value="Diagnosis"/>
      <fieldvalue value="Evaluation"/>
      <fieldvalue value="Management"/>
      <fieldvalue value="Technology Assessment"/>
    </field>
    <field fieldid="113" ordby="415" id="399" name="Clinical Specialty" type="picklist-many">
      <fieldvalue value="Internal Medicine"/>
      <fieldvalue value="Medical Genetics"/>
      <fieldvalue value="Obstetrics and Gynecology"/>
      <fieldvalue value="Oncology"/>
      <fieldvalue value="Pathology"/>
      <fieldvalue value="Surgery"/>
    </field>
    <field fieldid="114" ordby="420" id="400" name="Intended Users" type="picklist-many">
      <fieldvalue value="Advanced Practice Nurses"/>
      <fieldvalue value="Clinical Laboratory Personnel"/>
      <fieldvalue value="Hospitals"/>
      <fieldvalue value="Nurses"/>
      <fieldvalue value="Physician Assistants"/>
      <fieldvalue value="Physicians"/>
    </field>
    <field fieldid="129" ordby="425" id="401" name="Guideline Objective(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>To evaluate the clinical effectiveness and cost effectiveness of using the RD-100i OSNA system and the Metasin test to detect metastases in the sentinel lymph nodes of patients having breast cancer surgery</p></div>"/>
    </field>
    <field fieldid="132" ordby="430" id="402" name="Target Population" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>People with early invasive breast cancer who undergo a sentinel lymph node biopsy</p></div>"/>
    </field>
    <field fieldid="133" ordby="435" id="403" name="Interventions and Practices Considered" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Intraoperative tests (RD-100i OSNA system and Metasin test) for detecting lymph node metastases</p></div>"/>
    </field>
    <field fieldid="134" ordby="440" id="404" name="Major Outcomes Considered" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Diagnostic test accuracy </li>
    <li>Test failure rate </li>
    <li>Discordant test results </li>
    <li>Time to test result </li>
    <li>Clinical effectiveness including patient anxiety; number of repeat operations; time to start and nature of adjuvant therapy; morbidity and mortality from biopsies, axillary dissections, first and second operations, and treatment of cancer; and adverse events from false test results </li>
    <li>Cost-effectiveness </li>
</ul>"/>
    </field>
  </section>
  <section secid="405" ordby="500" name="Methodology">
    <field fieldid="109" ordby="505" id="406" name="Methods Used to Collect/Select the Evidence" type="picklist-many">
      <fieldvalue value="Hand-searches of Published Literature (Primary Sources)"/>
      <fieldvalue value="Hand-searches of Published Literature (Secondary Sources)"/>
      <fieldvalue value="Searches of Electronic Databases"/>
      <fieldvalue value="Searches of Unpublished Data"/>
    </field>
    <field fieldid="135" ordby="510" id="407" name="Description of Methods Used to Collect/Select the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Note from the National Guideline Clearinghouse (NGC)</strong>: The National Institute for Health and Care Excellence (NICE) commissioned an External Assessment Group to perform a systematic literature review on the technology considered in this diagnostics guidance and prepare a Diagnostics Assessment Report (DAR). The DAR for this guidance was prepared by Peninsula Technology Assessment Group (PenTAG), University of Exeter (see the &quot;Availability of Companion Documents&quot; field).</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Assessment of Clinical Effectiveness</span></strong></p>
<p><strong>Methods for Reviewing Effectiveness</strong></p>
<p><em>Identification of Studies</em></p>
<p>The following bibliographic databases were searched in this review: Medline, Medline in process and EMBASE (all via OVID), Web of Science (including conference proceedings, via Institute for Scientific Information [ISI]), the Cochrane Library (all) and Health Economic Evaluation Database (HEED, via the Cochrane Collaboration). The searches did not use any form of limit (e.g., date). See Appendix 3 in the DAR for details.</p>
<p>The following trials registries were also searched: National Institutes of Health (NIH) ClinicalTrials.gov, Current Controlled Trials, World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), European Union (EU) Clinical Trials Register. Google was also searched to identify grey literature and conference publications.</p>
<p>Items included after full-text screening were forward citation chased using Web of Science (Thompson Reuters). Searches were de-duplicated and managed using Endnote (X5).</p>
<p>Relevant studies were then identified in two stages. Titles and abstracts returned by the search strategy were examined independently by two researchers and screened for possible inclusion. Disagreements were resolved by discussion. Full texts of the identified studies were obtained. Two researchers examined these independently for inclusion or exclusion, and disagreements were again resolved by discussion.</p>
<p><em>Inclusion and Exclusion Criteria</em></p>
<p><span style=&quot;text-decoration: underline;&quot;>Population</span></p>
<p>Studies of individuals with invasive breast cancer who underwent a (sentinel) lymph node biopsy during the primary operation to excise a suspected breast cancer were included.</p>
<p><span style=&quot;text-decoration: underline;&quot;>Interventions and Comparators</span></p>
<p>Studies of OSNA or Metasin as used at the thresholds recommended by the manufacturer or designer were included.&amp;nbsp;</p>
<p>The reference standard was post-operative histopathology, performed on fresh sections of tissue.</p>
<p>Frozen section and touch imprint cytology were excluded as comparators as they were not felt to be sufficiently feasible for widespread implementation (or intervention).</p>
<p><span style=&quot;text-decoration: underline;&quot;>Outcomes</span></p>
<p>No study was excluded on the basis of outcomes, provided it appeared relevant to those listed in the decision problem.</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Test failure rate </li>
    <li>Diagnostic test accuracy </li>
    <li>Discordant test results </li>
    <li>Time to test result </li>
    <li>Duration of anaesthesia/time in operating theatre </li>
    <li>Number of repeat operations (except for re-excision of positive margins) </li>
    <li>Time to start and nature of adjuvant therapy </li>
</ul>
<p>The clinical outcomes for consideration include:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Patient anxiety associated with waiting time for result and not knowing the extent of surgery prior to operation </li>
    <li>Adverse events from false test results including patient distress and sequelae </li>
    <li>Morbidity and mortality from biopsies, axillary dissections, first and second operations and treatment of cancer </li>
</ul>
<p><span style=&quot;text-decoration: underline;&quot;>Study Design</span></p>
<p>For the review of test accuracy, the protocol made provision for all study designs unless evidence on the intervention and outcome of interest was already available from designs less open to bias as judged with reference to standard hierarchies of evidence.</p>
<p>Systematic reviews were used as a source for finding further studies and to compare with the Assessment Group's systematic review. For the purpose of this review, a systematic review was defined as one that has:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>A focused research question </li>
    <li>Explicit search criteria that are available to review, either in the document or on application </li>
    <li>Explicit inclusion/exclusion criteria, defining the population(s), intervention(s), comparator(s), and outcome(s) of interest </li>
    <li>A critical appraisal of included studies, including consideration of internal and external validity of the research </li>
    <li>A synthesis of the included evidence, whether narrative or quantitative </li>
</ul>
<p>Studies were excluded if they did not match the inclusion criteria, and in particular were:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Pre-clinical and animal </li>
    <li>Reviews, editorials and opinion pieces </li>
    <li>Case reports </li>
    <li>Studies with &amp;lt;10 participants </li>
</ul>
<p>Beyond this, no study design was excluded unless evidence on the intervention and outcome of interest is already available from study designs less open to bias as judged with reference to standard hierarchies of evidence.</p>
<p>See Appendix 3 in the DAR for detailed description of search strategy.</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Assessment of Cost-effectiveness: Systematic Review</span></strong></p>
<p><strong>Systematic Review of Existing Cost-effectiveness Evidence</strong></p>
<p><em>Search Strategy</em></p>
<p>The Assessment Group reviewed published economic evaluations of intraoperative molecular assessment for metastasis in early breast cancer to identify evidence relevant to current National Health Service (NHS) practice. In addition to electronic databases searched in the effectiveness section, the NHS Health Economic Evaluation Database (NHS HEED) and EconLit were searched for cost, cost-effectiveness and cost-utility studies. Forward citations of identified studies were searched for any relevant publications published after the initial search.</p>
<p>Relevant studies were then identified in two stages. Titles and abstracts returned by the search strategy were examined independently by two researchers and screened for possible inclusion. Disagreements were resolved by discussion. Full texts of the identified studies were obtained. Two researchers examined these independently for inclusion or exclusion, and disagreements were resolved by discussion.</p></div>"/>
    </field>
    <field fieldid="136" ordby="515" id="408" name="Number of Source Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Assessment of Clinical Effectiveness</strong></p>
<p>The electronic searches retrieved a total of 665 titles and abstracts. Fifty-nine additional papers were found by searching the bibliographies of included studies and by forward chasing. A total of 581 papers were excluded, based on screening title and abstract. Full text of the remaining 143 papers was requested for more in-depth screening, to give a total of 16 published and two unpublished papers included in the review. The process of study selection is shown in Figure 7 in the Diagnostics Assessment Report (DAR) (see the &quot;Availability of Companion Documents&quot; field). Fifty-eight abstracts were summarised but not reviewed.</p>
<p><strong>Assessment of Cost Effectiveness: Systematic Review</strong></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>The initial search identified a total of 13 abstracts, 7 of which were of conference presentations, and the remaining constituted 4 individual studies. Two studies were identified as relevant to the review. See Appendix 7 and Appendix 8 in the DAR (see &quot;the Availability of Companion Documents&quot; field) for details on excluded studies. </li>
    <li>The External Assessment Group submitted an economic model. </li>
</ul></div>"/>
    </field>
    <field fieldid="115" ordby="520" id="409" name="Methods Used to Assess the Quality and Strength of the Evidence" type="picklist-choice">
      <fieldvalue value="Expert Consensus (Committee)"/>
    </field>
    <field fieldid="149" ordby="525" id="410" name="Rating Scheme for the Strength of the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable</p></div>"/>
    </field>
    <field fieldid="116" ordby="530" id="411" name="Methods Used to Analyze the Evidence" type="picklist-many">
      <fieldvalue value="Meta-Analysis"/>
      <fieldvalue value="Review of Published Meta-Analyses"/>
      <fieldvalue value="Systematic Review with Evidence Tables"/>
    </field>
    <field fieldid="150" ordby="535" id="412" name="Description of the Methods Used to Analyze the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Note from the National Guideline Clearinghouse (NGC)</strong>: The National Institute for Health and Care Excellence (NICE) commissioned an External Assessment Group to perform a systematic literature review on the technology considered in this diagnostics guidance and prepare a Diagnostics Assessment Report (DAR). The DAR for this guidance was prepared by Peninsula Technology Assessment Group (PenTAG), University of Exeter (see the &quot;Availability of Companion Documents&quot; field).</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Assessment of Clinical Effectiveness</span></strong></p>
<p><strong>Methods of Reviewing Effectiveness</strong></p>
<p><em>Data Extraction Strategy</em></p>
<p>Data were extracted by one reviewer using a standardised data extraction form in Microsoft Access 2010 and checked by a second reviewer. Disagreements were resolved by discussion, with involvement of a third reviewer if necessary. Data extraction forms for each included study can be found in Appendix 4 in the DAR.</p>
<p><em>Critical Appraisal Strategy</em></p>
<p>The methodological quality of the studies was assessed, where applicable to the design of the study, according to criteria specified by the <em>Cochrane Collaboration's Tool for Assessing Risk of Bias</em>. The QUADAS-2 was used for test accuracy studies.</p>
<p>Quality was assessed by one reviewer and judgements were checked by a second. Any disagreement was resolved by discussion, with involvement of a third reviewer as necessary. Results were tabulated and the relevant aspects described in the data extraction forms.</p>
<p>See Sections 4.1.4.1 and 4.1.4.2 in the DAR for information in internal and external validity.</p>
<p><em>Methods of Data Synthesis</em></p>
<p>Details of the extracted data and quality assessment for each individual study are presented in structured tables and as a narrative description. Any possible effects of study quality on the effectiveness data are discussed. Data on test accuracy are presented as sensitivity, specificity and concordance, where available.</p>
<p><span style=&quot;text-decoration: underline;&quot;>Meta-analysis</span></p>
<p>Meta-analysis of diagnostic test accuracy was performed using the bivariate method implemented in Stata/SE 12.1 using the command metandi. Studies were only included in the meta-analysis if the numbers of true positives, true negatives, false negatives and false positives were all reported in the text or could be unambiguously inferred from other figures in the text. Meta-analysis using the full bivariate method was not performed where there were fewer than four included studies as the model cannot generally be estimated with fewer than four studies. Where the full bivariate model could not be estimated (either due to insufficient studies or other convergence errors) the Assessment Group reduced the complexity of the model by setting the correlation parameter to zero (effectively reducing the model to two independent univariate random effects analyses) and performing the analysis directly using the Stata command xtmelogit.</p>
<p>The bivariate method, when calculated using maximum likelihood estimation and without covariates, is equivalent to the hierarchical summary receiver operating characteristic (HSROC) model and this can be used to provide a summary receiver operating characteristic (SROC) curve and prediction region as well as a summary estimate and confidence region of sensitivity and specificity.</p>
<p>The SROC curve is designed to show how sensitivity and specificity are traded off against each other in different studies, through variation of the positivity threshold. If, and only if, there is reason to believe the positivity threshold might vary between studies, the Assessment Group provides a SROC curve and prediction region.</p>
<p>See Section 4 in the DAR for additional information on clinical effectiveness analysis.</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Assessment of Cost-effectiveness: Systematic Review</span></strong></p>
<p><strong>Systematic Review of Existing Cost-effectiveness Evidence</strong></p>
<p><em>Quality Appraisal</em></p>
<p>A quality appraisal was carried out on two studies retrieved in the economics literature search, using the Drummond checklist. A summary of the results are provided in Table 39 in the DAR.</p>
<p><strong>Independent ERG Assessment</strong></p>
<p>The main analysis compares OSNA and Metasin with histopathology from the perspective of the National Health Service (NHS). The evaluation is presented for the outcomes occurring up to the staging the axilla. In addition, a separate analysis evaluated the long-term outcomes of intra-operative testing options in terms of quality-adjusted life years (QALYs) and costs. The long-term analysis is intended as an illustration of the relative size of benefits of intra-operative diagnosis and the effect of uncertainty on its expected lasting impact.</p>
<p><em>Description of Model</em></p>
<p>The model is split into two separate sections (diagnostic and management) to encompass both immediate and long-term outcomes. As the technology is expected to have a larger impact on the short-term outcomes, it is this section that the Assessment Group particularly focusses on.</p>
<p><em>Diagnostic Pathway</em></p>
<p>Patients enter the model as those who have sentinel lymph node biopsy (SLNB) performed during their initial tumour removal. The model then splits into three different strategies, to encompass each of the possible combinations of diagnostic tests: intraoperative only (OSNA or Metasin, not in combination), histopathology only, or a combination of an intraoperative assay and follow up histopathology. These three strategies are shown in Figure 14 in the DAR. In the following descriptions, positive test results refer to results that indicate metastases in the sentinel lymph node. The three modelled pathways are therefore:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Current practice: SLNB is analysed using histopathology of the full node. If positive for metastases a second surgery is performed where axillary lymph node dissection (ALND) occurs. </li>
    <li>Add in strategy: half of the sentinel lymph node from SLNB is analysed during the tumour removal operation using one of the intraoperative tests (OSNA or Metasin). Those with a positive result receive ALND during that surgery. For those with a negative result, the other half of the sentinel lymph node is kept to be analysed with histopathology. Patients where metastases were not detected at the intraoperative stage, but whose histopathology is positive receive ALND as a second operation. </li>
    <li>Replacement strategy: the full sentinel lymph node is assessed by the intraoperative test, with no histopathology. Those with a positive result will receive ALND during their tumour removal. </li>
</ul>
<p>At this stage the intermediate costs and patient outcomes are calculated. This analysis was developed in Excel.</p>
<p>See Section 5 in the DAR for additional information on the assessment of cost-effectiveness.</p></div>"/>
    </field>
    <field fieldid="112" ordby="540" id="413" name="Methods Used to Formulate the Recommendations" type="picklist-choice">
      <fieldvalue value="Expert Consensus"/>
    </field>
    <field fieldid="145" ordby="545" id="414" name="Description of Methods Used to Formulate the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Developing Recommendations</strong></p>
<p>After reviewing the evidence the Diagnostic Advisory Committee (DAC) agrees draft recommendations on the use of the technology in the National Health Service (NHS) in England. When formulating these recommendations, the Committee has discretion to consider those factors it believes are most appropriate to the evaluation. In doing so, the Committee has regard to any relevant provisions of the National Institute for Health and Care Excellence's (NICE's) Directions, set out by the Secretary of State for Health, and legislation on human rights, discrimination and equality. In undertaking evaluations of healthcare technologies, NICE takes into account the broad balance of clinical benefits and costs, the degree of clinical need of patients under consideration, any guidance issued to the NHS by the Secretary of State that is specifically drawn to the attention of NICE by the Secretary of State, and any guidance issued by the Secretary of State, and the potential for long-term benefits to the NHS of innovation.</p>
<p>The Committee takes into account advice from NICE on the approach it should take to making scientific and social value judgements. Advice on social value judgements is informed in part by the work of NICE's Citizens Council.</p>
<p>The Committee takes into account how its judgements have a bearing on distributive justice or legal requirements in relation to human rights, discrimination and equality. Such characteristics include, but are not confined to: race, gender, disability, religion or belief, sexual orientation, gender reassignment and pregnancy or maternity.</p>
<p>The Committee considers the application of other Board-approved NICE methods policies, such as the supplementary guidance on discounting and the end-of-life criteria, if they are relevant to the evaluation.</p>
<p>Because the Programme often evaluates new technologies that have a thin evidence base, in formulating its recommendations the Committee balances the quality and quantity of evidence with the expected value of the technology to the NHS and the public.</p>
<p>The credibility of the guidance produced by NICE depends on the transparency of the DAC's decision-making process. It is crucial that the DAC's decisions are explained clearly, and that the contributions of registered stakeholders and the views of members of the public are considered. The reasoning behind the Committee's recommendations is explained, with reference to the factors that have been taken into account.</p>
<p>The language and style used in the documents produced by the Committee are governed by the following principles:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Clarity is essential in explaining how the DAC has come to its conclusions. </li>
    <li>The text of the documents does not need to reiterate all the factual information that can be found in the information published alongside the guidance. This needs careful judgement so that enough information and justification is given in the recommendations to enable the reader to understand what evidence the DAC considered and, if appropriate, who provided that evidence. </li>
</ul>
<p>The Committee may take into account factors that may provide benefits to the NHS or the population, such as patient convenience. It may also consider costs and other positive or negative impacts on the NHS that may not be captured in the reference-case cost analysis, such as improved processes.</p></div>"/>
    </field>
    <field fieldid="146" ordby="550" id="415" name="Rating Scheme for the Strength of the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable</p></div>"/>
    </field>
    <field fieldid="148" ordby="565" id="417" name="Cost Analysis" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The cost-effectiveness analyses of the short-term outcomes examined the diagnostic accuracy of the intraoperative tests compared with postoperative, histopathology, and the disutility of waiting for histopathology results and having a second operation. For strategies that did not involve histopathology, the utility was 1 because there was no wait for test results or any second operations directly resulting from the intraoperative test. Only short-term quality-adjusted life-year (QALY) gains were included in these analyses.</p>
<p>Using the National Health Service (NHS) reference costs in the short-term model, whole-node OSNA analysis and half-node OSNA analysis dominated histopathology analysis because they were less costly and more effective. Whole-node OSNA analysis also dominated half-node OSNA analysis. It was estimated that 4.1% of the 76.5% of patients who received a negative test result from half-node OSNA analysis would end up with a positive result while waiting for confirmation by histopathology analysis, compared with 20% of patients who would receive a positive result using postoperative histopathology analysis alone.</p>
<p>In the short-term model, whole-node and half-node Metasin analyses dominated histopathology analysis because they were less costly and more effective. Whole-node Metasin also dominated half-node Metasin analysis. It was estimated that, of the 78.5% of patients who received a negative result by half-node Metasin analysis, 1.9% would receive a positive result while waiting for confirmation by histopathology analysis, compared with 20% of patients who would receive a positive result using postoperative histopathology analysis alone.</p>
<p>The cost-effectiveness analyses of the long-term outcomes examined all the costs and benefits from accurate diagnosis through to improved patient management. In these analyses, the diagnostic strategies were ordered by the number of QALYs associated with them, with whole-node OSNA analysis producing the least QALYs (9.22) and postoperative histopathology producing the most QALYs (9.32). The QALY difference is equal to 0.1 (that is, equivalent to 5 weeks of full-health life) and this difference occurs because the higher accuracy of histopathology assumed in the model leads to more correct diagnoses and appropriate subsequent treatment.</p>
<p>Using the NHS reference costs in the long-term model, the incremental cost-effectiveness ratio (ICER) was &amp;pound;4324 saved per QALY lost for whole-node OSNA analysis compared with histopathology analysis and &amp;pound;24,863 saved per QALY lost for whole-node Metasin analysis compared with histopathology analysis. The ICERs for whole-node analysis compared with histopathology analysis suggest that the intraoperative testing strategies save money but that there is a loss of approximately 0.1 QALY, compared with histopathology analysis.</p>
<p><strong>Considerations</strong></p>
<p>The Committee considered the unpublished non-peer reviewed evidence for the Metasin test. The Committee acknowledged the findings of the 2 draft unpublished studies, but noted that the studies had not been peer reviewed and therefore the results should be interpreted with caution. The Committee concluded that the test appeared promising but that there was too much uncertainty associated with the evidence to recommend use of the test in routine&amp;nbsp;National Health Service (NHS) practice. The Committee was encouraging of further research on this test.</p>
<p>The Committee acknowledged that the model contained several assumptions that could potentially increase the uncertainty of the cost-effectiveness analysis. The Committee was of the view that, if the economic model used a more realistic cost for histopathology, it would indicate that the RD-100i OSNA system was less cost-effective than the base-case ICERs presented in the Diagnostics Assessment Report (DAR). However, given all of the uncertainty in the cost-effectiveness analyses (see section 6.13 in the original guideline document), the Committee concluded that the RD-100i OSNA system was still likely to be a cost-effective use of NHS resources.</p>
<p>See Sections 5 and 6 in the original guideline document for more information on cost-effectiveness.</p></div>"/>
    </field>
    <field fieldid="104" ordby="570" id="418" name="Method of Guideline Validation" type="picklist-choice">
      <fieldvalue value="External Peer Review"/>
    </field>
    <field fieldid="130" ordby="575" id="419" name="Description of Method of Guideline Validation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The National Institute for Health and Care Excellence (NICE) sends the Diagnostics Assessment Report (DAR), with any confidential material removed, to registered stakeholders for comment. Stakeholders have 10 working days to return comments. Models supporting the DAR are made available to registered stakeholders on request during this period.</p>
<p>NICE presents anonymised registered stakeholder comments on the DAR, along with any responses from NICE or the External Assessment Group (EAG), to the Committee and later publishes these comments on its website.</p></div>"/>
    </field>
  </section>
  <section secid="424" ordby="600" name="Evidence Supporting the Recommendations">
    <field fieldid="139" ordby="610" id="426" name="Type of Evidence Supporting the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The type of evidence supporting the recommendations is not specifically stated.</p>
<p>The Diagnostics Advisory Committee considered clinical and cost-effectiveness evidence from a systematic review and economic evaluation of intraoperative tests (RD-100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer prepared by an External Review Group.</p></div>"/>
    </field>
  </section>
  <section secid="427" ordby="700" name="Benefits/Harms of Implementing the Guideline Recommendations">
    <field fieldid="152" ordby="705" id="428" name="Potential Benefits" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The intention is that the intraoperative test results are available during surgery and may be used to determine if other axillary lymph nodes should be removed at the same time as the initial tumour. This could avoid the need for a second operation and allow subsequent treatments such as chemotherapy to begin earlier.</p></div>"/>
    </field>
    <field fieldid="153" ordby="710" id="429" name="Potential Harms" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Adverse events from false test results, including patient distress and sequelae</p></div>"/>
    </field>
  </section>
  <section secid="432" ordby="900" name="Qualifying Statements">
    <field fieldid="137" ordby="905" id="433" name="Qualifying Statements" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>This guidance represents the view of the National Institute for
    Health and Care Excellence (NICE), which was arrived at after careful
    consideration of the evidence available. Healthcare professionals are
    expected to take it fully into account when exercising their clinical
    judgement. However, the guidance does not override the individual
    responsibility of healthcare professionals to make decisions appropriate
    to the circumstances of the individual patient, in consultation with
    the patient and/or guardian or carer. </li>
    <li>Implementation of this guidance is the responsibility of local
    commissioners and/or providers. Commissioners and providers are reminded
    that it is their responsibility to implement the guidance, in their
    local context, in light of their duties to have due regard to the need
    to eliminate unlawful discrimination, advance equality of opportunity
    and foster good relations. Nothing in this guidance should be
    interpreted in a way that would be inconsistent with compliance with
    those duties. </li>
</ul>"/>
    </field>
  </section>
  <section secid="434" ordby="1000" name="Implementation of the Guideline">
    <field fieldid="131" ordby="1010" id="436" name="Description of Implementation Strategy" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The National Institute for Health and Care Excellence (NICE) has developed <a href=&quot;http://www.nice.org.uk/guidance/dg8/resources&quot; title=&quot;NICE Web site&quot;>tools</a> (see also the &quot;Availability of Companion Documents&quot; field) to help organisations put this guidance into practice.</p></div>"/>
    </field>
    <field fieldid="117" ordby="1015" id="437" name="Implementation Tools" type="picklist-many">
      <fieldvalue value="Mobile Device Resources"/>
      <fieldvalue value="Patient Resources"/>
      <fieldvalue value="Resources"/>
    </field>
  </section>
  <section secid="439" ordby="1100" name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <field fieldid="50" ordby="1105" id="440" name="IOM Care Need" type="picklist-many">
      <fieldvalue value="Living with Illness"/>
    </field>
    <field fieldid="51" ordby="1110" id="441" name="IOM Domain" type="picklist-many">
      <fieldvalue value="Effectiveness"/>
      <fieldvalue value="Patient-centeredness"/>
    </field>
  </section>
  <section secid="442" ordby="1200" name="Identifying Information and Availability">
    <field fieldid="97" ordby="1201" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>National Institute for Health and Care Excellence (NICE). Intraoperative tests (RD-100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer. London (UK): National Institute for Health and Care Excellence (NICE); 2013 Aug. 40 p.&amp;nbsp;(Diagnostics guidance; no. 8).&amp;nbsp;</td></tr></table>"/>
    </field>
    <field fieldid="124" ordby="1205" id="443" name="Adaptation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable: The guideline was not adapted from another source.</p></div>"/>
    </field>
    <field fieldid="128" ordby="1215" id="445" name="Date Released" type="text">
      <fieldvalue value="2013 Aug"/>
    </field>
    <field fieldid="158" ordby="1225" id="447" name="Guideline Developer(s)" type="orglist-p">
      <fieldvalue value="National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]"/>
    </field>
    <field fieldid="125" ordby="1235" id="449" name="Source(s) of Funding" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>National Institute for Health and Care Excellence (NICE)</p></div>"/>
    </field>
    <field fieldid="126" ordby="1240" id="450" name="Guideline Committee" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Diagnostics Advisory Committee</p></div>"/>
    </field>
    <field fieldid="127" ordby="1245" id="451" name="Composition of Group That Authored the Guideline" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><em>Standing Committee Members</em>: Professor Ron Akehurst, Professor in Health Economics, School of Health &amp;amp; Related Research (ScHARR), University of Sheffield; Dr Trevor Cole, Consultant Clinical and Cancer Geneticist, Birmingham Women's Hospital; Dr Paul Collinson, Consultant Chemical Pathologist, St George's Hospital; Dr Sue Crawford, General Practitioner (GP) Principal, Chillington Health Centre; Professor Ian A Cree, Senior Clinical Advisor, NIHR Evaluation Trials and Studies Coordinating Centre, University of Southampton; Professor Erika Denton, National Clinical Director for Imaging, Department of Health, Honorary Professor of Radiology, University of East Anglia and Norfolk &amp;amp; Norwich University Hospital; Dr Steve Edwards ,Head of Health Technology Assessment, BMJ Evidence Centre; Mr David Evans, Lay representative; Dr Simon Fleming, Consultant in Clinical Biochemistry and Metabolic Medicine, Royal Cornwall Hospital; Professor Lisa Hall, Professor of Analytical Biotechnology, University of Cambridge; Professor Noor Kalsheker, Professor of Clinical Chemistry, University of Nottingham; Dr Gail Norbury, Consultant Clinical Scientist, Guy's and St Thomas' NHS Foundation Trust; Dr Mark Kroese<em> (Vice Chair</em>), Consultant in Public Health Medicine, PHG Foundation, Cambridge and UK Genetic Testing Network; Dr Peter Naylor, GP, Chair Wirral Health Commissioning Consortia; Professor Adrian Newland (<em>Chair</em>); Dr Richard Nicholas, Consultant Neurologist, Honorary Senior Lecturer, Heatherwood and Wexham Park Hospitals; Ms Margaret Ogden, Lay representative; Dr Diego Ossa, Director of Market Access Europe, Novartis Molecular Diagnostics; Mr Stuart Saw, Director of Finance, North East London and the City PCTs; Professor Mark Sculpher, Professor of Health Economics at the Centre for Health Economics, University of York; Dr Steve Thomas, Consultant Vascular and Cardiac Radiologist at Sheffield Teaching Hospitals Foundation Trust; Mr Paul Weinberger, CEO, DiaSolve Ltd, London; Mr Christopher Wiltsher, Lay representative</p>
<p><em>Specialist Committee Members</em>: Ms Marie Hecht, Lay member; Professor Ian Kunkler, Consultant and Honorary Professor in Clinical Oncology, Edinburgh Cancer Centre; Professor Graham T Layer, Consultant surgeon and Director of Professional Standards, Royal Surrey County Hospital NHS Foundation Trust; Mr Simon Pain, Consultant Breast and Endocrine Surgeon, Norfolk and Norwich University Hospital; Mr Zenon Rayter, Consultant surgeon, North Bristol NHS Trust; Dr Deirdre Ryan, Consultant pathologist, Barts Health NHS Trust; Dr Abeer Shaaban, Consultant pathologist, St James's University Hospital</p></div>"/>
    </field>
    <field fieldid="147" ordby="1250" id="452" name="Financial Disclosures/Conflicts of Interest" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Committee members are required to submit a declaration of interests on appointment, in every year of their tenure, and at each Committee meeting, in line with the National Institute for Health and Care Excellence's (NICE's) code of practice for declaring and dealing with conflicts of interest.</p></div>"/>
    </field>
    <field fieldid="120" ordby="1256" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p>
<p>This guideline meets NGC's 2013 (revised) inclusion criteria.</p></div>"/>
    </field>
    <field fieldid="118" ordby="1260" id="454" name="Guideline Availability" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Electronic copies: Available from the <a href=&quot;http://www.nice.org.uk/guidance/dg8&quot; title=&quot;NICE Web site&quot;>National Institute for Health and Care Excellence (NICE) Web site</a>. Also available for download as a Kindle or EPUB ebook from the <a href=&quot;http://www.nice.org.uk/guidance/dg8&quot; title=&quot;NICE Web site&quot;>NICE Web site</a>.</p></div>"/>
    </field>
    <field fieldid="119" ordby="1265" id="455" name="Availability of Companion Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The following are available:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Huxley N, Jones-Hughes T, Coelho H, Snowsill T, Cooper C, Meng Y, Cooper K, Hyde C, Mujica-Mota R. A systematic review and economic evaluation of intraoperative tests (RD-100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer. Diagnostics assessment report. Exeter (UK): Peninsula Technology Assessment Group (PenTAG), Peninsula College of Medicine and Dentistry, University of Exeter; 2012. 168 p. Electronic copies: Available from the <a href=&quot;http://www.nice.org.uk/guidance/dg8/evidence&quot; title=&quot;NICE Web site&quot;>National Institute for Health and Care Excellence (NICE) Web site</a>. </li>
    <li>Huxley N, Jones-Hughes T, Coelho H, Snowsill T, Cooper C, Meng Y, Cooper K, Hyde C, Mujica-Mota R. A systematic review and economic evaluation of intraoperative tests (RD-100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer. Diagnostics assessment report appendices. Exeter (UK): Peninsula Technology Assessment Group (PenTAG), Peninsula College of Medicine and Dentistry, University of Exeter; 2012. 144 p. Electronic copies: Available from the <a href=&quot;https://www.nice.org.uk/guidance/dg8/resources/intraoperative-tests-rd100i-osna-system-and-metasin-test-for-detecting-sentinel-lymph-node-metastases-in-breast-cancer-diagnostic-assessment-report-appendices2&quot; title=&quot;NICE Web site&quot;>NICE Web site</a>. </li>
    <li>Huxley N, Jones-Hughes T, Coelho H, Snowsill T, Cooper C, Meng Y, Cooper K, Hyde C, Mujica-Mota R. A systematic review and economic evaluation of intraoperative tests (RD-100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer. Diagnostics assessment report errata. Exeter (UK): Peninsula Technology Assessment Group (PenTAG), Peninsula College of Medicine and Dentistry, University of Exeter; 2012. 16 p. Electronic copies: Available from the <a href=&quot;https://www.nice.org.uk/guidance/dg8/resources/intraoperative-tests-rd100i-osna-system-and-metasin-test-for-detecting-sentinel-lymph-node-metastases-in-breast-cancer-diagnostic-assessment-report-errata2&quot; title=&quot;NICE Web site&quot;>NICE Web site</a>. </li>
    <li>Intraoperative tests (RD-100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer. Costing template. London (UK): National Institute for Health and Care Excellence; 2013 Aug. (Diagnostics guidance; no. 8). Electronic copies: Available from the <a href=&quot;https://www.nice.org.uk/guidance/dg8/resources&quot; title=&quot;NICE Web site&quot;>NICE Web site</a>. </li>
    <li>Intraoperative tests (RD-100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer. Podcast with Mr Zenon Rayter. London (UK): National Institute for Health and Care Excellence; 2013 Aug. (Diagnostics guidance; no. 8). Electronic copies: Available from the <a href=&quot;https://www.nice.org.uk/guidance/dg8/resources&quot; title=&quot;NICE Web site&quot;>NICE Web site</a>. </li>
    <li>Diagnostics Assessment Programme manual. London (UK): National Institute for Health and Care Excellence; 2011 Dec. 130 p. Electronic copies: Available from the <a href=&quot;http://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-diagnostics-guidance/Diagnostics-assessment-programme-manual.pdf&quot; title=&quot;NICE Web site&quot;>NICE Web site</a>. </li>
</ul></div>"/>
    </field>
    <field fieldid="143" ordby="1275" id="457" name="Patient Resources" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The following is available:</p>
<ul ytpe=&quot;disc&quot;>
    <li>Intraoperative tests (RD-100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer: information for the public. London (UK): National Institute for Health and Care Excellence (NICE); 2013 Aug. (Diagnostics guidance; no. 8). Electronic copies: Available from the <a href=&quot;http://www.nice.org.uk/guidance/dg8/informationforpublic&quot; title=&quot;NICE Web site&quot;>National Institute for Health and Care Excellence (NICE) Web site</a>. </li>
</ul>
<p class=&quot;Disclaimer&quot;>Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.</p></div>"/>
    </field>
    <field fieldid="142" ordby="1280" id="458" name="NGC Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary was completed by ECRI Institute on December 31, 2014.</p>
<p>The National Institute for Health and Care Excellence (NICE) has granted the National Guideline Clearinghouse (NGC) permission to include summaries of their Diagnostics guidance with the intention of disseminating and facilitating the implementation of that guidance. NICE has not verified this content to confirm that it accurately reflects the original NICE guidance and therefore no guarantees are given by NICE in this regard. All NICE diagnostics guidance is prepared in relation to the National Health Service in England and Wales. NICE has not been involved in the development or adaptation of NICE guidance for use in any other country. The full versions of all NICE guidance can be found at <a href=&quot;http://www.nice.org.uk&quot; title=&quot;NICE Web site&quot;>www.nice.org.uk</a>.</p></div>"/>
    </field>
    <field fieldid="141" ordby="1290" id="460" name="Copyright Statement" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.</p></div>"/>
    </field>
  </section>
  <section secid="99999" ordby="99999" name="Disclaimer">
    <field fieldid="99999" ordby="99999" id="99999" name="NGC Disclaimer" type="text">
      <fieldvalue value="<p>The National Guideline Clearinghouse (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;>NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p>"/>
    </field>
  </section>
</version><!--
     FILE ARCHIVED ON 00:19:49 Jul 13, 2018 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 23:48:26 Jul 15, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 69.955 (3)
  esindex: 0.009
  captures_list: 90.613
  CDXLines.iter: 13.64 (3)
  PetaboxLoader3.datanode: 58.768 (4)
  exclusion.robots: 0.505
  exclusion.robots.policy: 0.488
  RedisCDXSource: 2.377
  PetaboxLoader3.resolve: 93.846
  load_resource: 126.427
-->